INSON PAPILLOMA VIRUSI PERSISTENSIYASI BO‘LGAN AYOLLARDA INDIVIDUAL KLINIK BOSHQARUV ALGORITMINI TAKOMILLASHTIRISH
Ключевые слова:
persistent HPVАннотация
Mazkur maqolada persistent inson papilloma virusi (HPV) infeksiyasi boʻlgan ayollarni klinik boshqarishning zamonaviy yondashuvlari hamda individual klinik boshqaruv algoritmini takomillashtirish masalalari yoritilgan. Ilmiy adabiyotlar asosida persistent HPV infeksiyasining bachadon boʻyni saratoni va servikal intraepitelial neoplaziya rivojlanishidagi oʻrni, yuqori onkogen xavfli HPV genotiplarining klinik ahamiyati, skrining usullari hamda amaldagi klinik algoritmlarning afzallik va cheklovlari baholangan. Shuningdek, HPV genotipi, virus persistensiyasining davomiyligi, sitologik va kolposkopik tekshiruv natijalari, p16/Ki-67 immunoboʻyash, DNK metillanish biomarkerlari hamda bemorning individual klinik omillariga asoslangan takomillashtirilgan boshqaruv algoritmi taklif etilgan. Ushbu yondashuv diagnostik aniqlikni oshirish, keraksiz invaziv muolajalarni kamaytirish, yuqori xavf guruhidagi ayollarni oʻz vaqtida aniqlash hamda bachadon boʻyni saratoni profilaktikasi samaradorligini oshirishga xizmat qilishi mumkin.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. The Lancet Global Health, 8(2), e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6
2. Perkins, R. B., Guido, R. S., Castle, P. E., Chelmow, D., Einstein, M. H., Garcia, F., Huh, W. K., Kim, J. J., Moscicki, A. B., Nayar, R., Saraiya, M., Sawaya, G. F., Wentzensen, N., & Schiffman, M. (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 24(2), 102–131. https://doi.org/10.1097/LGT.0000000000000525
3. Cheung, L. C., Egemen, D., Chen, X., Katki, H. A., Demarco, M., Wiser, A. L., Perkins, R. B., Guido, R. S., Wentzensen, N., & Schiffman, M. (2020). 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation. Journal of Lower Genital Tract Disease, 24(2), 90–101. https://doi.org/10.1097/LGT.0000000000000528
4. Elfgren, K., Elfström, K. M., Naucler, P., Arnheim-Dahlström, L., & Dillner, J. (2017). Management of women with human papillomavirus persistence: Long-term follow-up of a randomized clinical trial. American Journal of Obstetrics and Gynecology, 216(3), 264.e1–264.e7. https://doi.org/10.1016/j.ajog.2016.10.042
5. Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016). Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2, 16086. https://doi.org/10.1038/nrdp.2016.86
6. Arbyn, M., Smith, S. B., Temin, S., Sultana, F., & Castle, P. (2021). Detecting cervical precancer and reaching under-screened women by using HPV testing on self samples: Updated meta-analysis. BMJ, 374, n1904. https://doi.org/10.1136/bmj.n1904
7. Wentzensen, N., Clarke, M. A., Perkins, R. B., et al. (2023). Impact of HPV genotyping, cytology and biomarkers in cervical cancer screening. Journal of Lower Genital Tract Disease. https://doi.org/10.1097/LGT.0000000000000788
8. Bosch, F. X., Lorincz, A., Muñoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55(4), 244–265. https://doi.org/10.1136/jcp.55.4.244
9. Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013). Human papillomavirus and cervical cancer. The Lancet, 382(9895), 889–899. https://doi.org/10.1016/S0140-6736(13)60022-7
10. Ronco, G., Dillner, J., Elfström, K. M., et al. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer. The Lancet, 383(9916), 524–532. https://doi.org/10.1016/S0140-6736(13)62218-7
11. Schiffman, M., Wentzensen, N., Perkins, R. B., & Guido, R. S. (2021). An introduction to the 2019 ASCCP Risk-Based Management Guidelines. Journal of Lower Genital Tract Disease, 25(2), 87–89. https://doi.org/10.1097/LGT.0000000000000602
12. Clarke, M. A., Cheung, L. C., Castle, P. E., et al. (2019). Five-year risk of cervical precancer following HPV testing. JAMA Oncology, 5(2), 181–188. https://doi.org/10.1001/jamaoncol.2018.4279
13. Arbyn, M., Verdoodt, F., Snijders, P. J. F., et al. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples. The Lancet Oncology, 15(2), 172–183. https://doi.org/10.1016/S1470-2045(13)70570-9
14. Castle, P. E., Stoler, M. H., Wright, T. C., Sharma, A., Wright, T. L., & Behrens, C. M. (2011). Performance of carcinogenic HPV DNA testing. American Journal of Clinical Pathology, 136(4), 578–586. https://doi.org/10.1309/AJCPHQRJXQXWQKPN
15. Wentzensen, N., Schiffman, M., Silver, M. I., et al. (2017). ASCCP Colposcopy Standards: Risk-based colposcopy practice. Journal of Lower Genital Tract Disease, 21(4), 230–234. https://doi.org/10.1097/LGT.0000000000000323
16. Demarco, M., Egemen, D., Raine-Bennett, T. R., et al. (2020). A study of type-specific HPV natural history and implications for management. Journal of Lower Genital Tract Disease, 24(2), 132–143. https://doi.org/10.1097/LGT.0000000000000529
17. Schiffman, M., Hyun, N., Raine-Bennett, T., et al. (2021). A cohort study of cervical screening using HPV testing. JAMA Oncology, 7(12), 1834–1842. https://doi.org/10.1001/jamaoncol.2021.3908
18. World Health Organization. (2021). WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva: WHO.
19. World Health Organization. (2020). Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO.
20. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
